Compare XWEL & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XWEL | XRTX |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.4M |
| IPO Year | N/A | N/A |
| Metric | XWEL | XRTX |
|---|---|---|
| Price | $0.46 | $0.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.9K | ★ 48.5K |
| Earning Date | 11-14-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,523,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $0.51 |
| 52 Week High | $1.62 | $1.79 |
| Indicator | XWEL | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 19.01 | 50.72 |
| Support Level | $0.43 | $0.58 |
| Resistance Level | $0.48 | $0.62 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 9.55 | 82.27 |
XWELL Inc is a health and wellness holding company. It is an airport retailer of spa services through XpresSpa locations, offering travelers premium spa services, including massage, nail, and skincare, as well as spa and travel products. It operates four reportable operating segments: XpresSpa. XpresTest, Naples Wax Center and Treat. XpresSpa provides travelers with premium spa services, including massage, nail and skin care, as well as spa and travel products. Treat is a travel health and wellness brand that offers in-airport spa. XpresTest provides COVID-19 screening and diagnostic testing in partnership with the CDC. Naples Wax Center operates three high-performing locations with core products and service offerings from face and body waxing to a range of skincare and cosmetic products.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.